文献速递肿瘤 PET/CT

EANM/EARL在PET定量中的协调策略:从日常实践到多中心肿瘤研究

EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-06-16

该综述阐述PET/CT定量参数协调化的动机与方法,重点介绍EANM Research Ltd.(EARL)FDG PET/CT认证项目,该项目旨在将FDG PET用作定量影像生物标志物。文章描述EARL认证在多种肿瘤类型中协调SUV和MATV的验证,涉及EORTC标准、PERCIST及Deauville评分等疗效评估标准,并报告对51个EARL认证中心的调查结果。

要点

  • 多中心定量PET/CT要求SUV、MATV、TLG等参数在患者和站点间可比。
  • EARL FDG PET/CT认证项目旨在将FDG PET用作定量影像生物标志物。
  • 对51个EARL认证中心的调查报告了项目实施及对日常 routine 和临床试验的影响。

核心结论

  • 该综述描述了定量PET/CT性能协调化的动机与方法,重点介绍EARL FDG PET/CT认证项目,并讨论未来认证举措。

研究设计与样本

  • 综述,描述定量PET/CT性能协调化的动机与方法,重点介绍EANM Research Ltd.(EARL)FDG PET/CT认证项目,并讨论未来认证举措。
  • 报告了一项对51个EARL认证中心的调查结果。

主要发现

  • EARL认证项目在多种肿瘤类型中验证了SUV和MATV的协调化,重点涉及使用EORTC标准、PERCIST或Deauville评分等基于肝脏的评估进行疗效评估。
  • 对51个EARL认证中心的调查报告了项目如何实施及其对日常 routine 和临床试验的影响,以及MATV和异质性特征等新指标的协调化。

关键数值与推荐

  • 使用EORTC标准或PERCIST进行疗效评估,以及使用Deauville评分等基于肝脏的评估。
  • 定量参数包括标准化摄取值(SUV)、代谢活性肿瘤体积(MATV)或总病灶糖酵解(TLG)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Quantitative positron emission tomography/computed tomography (PET/CT) can be used as diagnostic or prognostic tools (i.e. single measurement) or for therapy monitoring (i.e. longitudinal studies) in multicentre studies. Use of quantitative parameters, such as standardized uptake values (SUVs), metabolic active tumor volumes (MATVs) or total lesion glycolysis (TLG), in a multicenter setting requires that these parameters be comparable among patients and sites, regardless of the PET/CT system used. This review describes the motivations and the methodologies for quantitative PET/CT performance harmonization with emphasis on the EANM Research Ltd. (EARL) Fluorodeoxyglucose (FDG) PET/CT accreditation program, one of the international harmonization programs aiming at using FDG PET as a quantitative imaging biomarker. In addition, future accreditation initiatives will be discussed. The validation of the EARL accreditation program to harmonize SUVs and MATVs is described in a wide range of tumor types, with focus on therapy assessment using either the European Organization for Research and Treatment of Cancer (EORTC) criteria or PET Evaluation Response Criteria in Solid Tumors (PERCIST), as well as liver-based scales such as the Deauville score. Finally, also presented in this paper are the results from a survey across 51 EARL-accredited centers reporting how the program was implemented and its impact on daily routine and in clinical trials, harmonization of new metrics such as MATV and heterogeneity features.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Aide N, Lasnon C, Veit-Haibach P, et al. EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies. Eur J Nucl Med Mol Imaging. 2017. PMID: 28623376. doi:10.1007/s00259-017-3740-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。